NanoViricides Measles Drug Development Animal Study is Imminent
SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with its Measles drug development program.
The Company has commissioned an animal trial to evaluate certain drug candidates in a lethal animal infection model. The Company has secured specially modified mice that bear the human form of CD150/SLAM protein that the Measles virus requires to enter cells. The Company will initiate the study as soon as the animals arrive and are acclimatized at the animal study laboratory.
"NV-387 actually cured lethal RSV infection in animals, and Measles is a cousin of RSV," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding, "This gives us confidence that NV-387 will have strong activity against Measles virus as well."
NV-387 is a clinical stage broad-spectrum antiviral drug that is designed to act as a decoy of a cell, attacking the virus by presenting to it the very features that the virus requires for binding to the cell, and upon binding, destroying the virus particle so it cannot infect. Over 90-95% of human pathogenic viruses require the sulfated proteoglycan feature that NV-387 presents to the virus.
There is no approved drug for the treatment of Measles virus infection. Recently, CDC included Vitamin A as part of the standard of care for Measles infection. Vitamin A is known to help malnourished children with Measles, but its role as supplementary addition to non-deficient patients is not known. CDC also recommended use of ribavirin in extreme cases as a last resort. Ribavirin is a toxic nucleoside analog and is not approved for treatment of Measles.
Thus there is a clear unmet need for a Measles drug. NV-387, a clinical stage drug can be rapidly developed to meet this need. The animal study of effectiveness of NV-387 in h-SLAM-modified mice will provide important information regarding potential human effectiveness of NV-387 to treat Measles virus infection.
Measles outbreaks have continued to expand in the US, reaching a record 1,088 confirmed cases across 33 jurisdictions from January 1 through May 29, 2025 according to CDC (https://www.cdc.gov/measles/data-research/index.html). Europe has witnessed a dramatic ten-fold increase in measles cases last year, i.e. 2024, over 2023.
Measles vaccination rates have been declining in the USA since the COVID pandemic, according to a June 3, 2025 Johns Hopkins University news report (https://hub.jhu.edu/2025/06/03/united-states-measles-vaccination-rate-declines/). The average county-level MMR vaccination rate in the USA fell from 93.92% pre-pandemic to 91.26% post-pandemic, moving well below the 95% herd immunity threshold that is generally regarded as providing community or herd immunity.
Additionally, Measles vaccine failure cases have also been increasing according to the European data, which is an important cause for concern. It is likely that the increase in vaccine failure rate may be due to the increase in a new genotype, D8 of the Measles virus, replacing the previous dominant B3 genotype. The B3 genotype is closer to the Measles vaccine live attenuated Enders-Edmonton "Moraten" strain that has been used in the USA since 1968.
The changing genotypes suggest that the Measles virus is likely drifting away from the current vaccine.
In this global scenario, NV-387, the clinical stage broad-spectrum, host-mimetic antiviral nanomedicine drug could perhaps be the only currently available drug candidate to combat the Measles virus and disease.
Measles cases in Europe were over 35,000 in 2024, an almost ten-fold increase from 2023, according to the annual report of European Center for Disease Prevention and Control (ECDC). Only approximately 87% of cases were in unvaccinated persons, and 13% of the cases were of vaccine failure, out of the cases with known vaccination status.
The significant Measles vaccine failure rate observed in Europe is alarming, considering that the two-dose vaccine is supposed to be 97% effective. Overall, childhood vaccination in Europe was about 94% and declining. This rate is below the 95% considered the threshold for achieving "herd" or community immunity.
Given the various causes of vaccine failure, and of vaccine hesitancy, attaining 95% vaccine coverage cannot be considered a very probable solution for combating the Measles epidemic. An effective drug is needed to combat the epidemic.
ABOUT NANOVIRICIDESNanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact: NanoViricides, Inc. info@nanoviricides.com
Public Relations Contact: ir@nanoviricides.com
SOURCE: NanoViricides
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Suspected case of Measles under investigation in Lee County, Alabama
LEE COUNTY, Ala. (WRBL) — The Alabama Department of Public Health (ADPH) is investigating a suspected case of measles in Lee County involving an unvaccinated individual who was not yet eligible to receive the vaccine. The case is currently under review as part of ADPH's standard communicable disease response. Health officials say while the individual is confirmed to be unvaccinated, they were too young to have received the measles, mumps, and rubella (MMR) vaccine. The ADPH is now working closely with local medical providers to identify any other unvaccinated individuals who may need the MMR vaccine as a precaution. 'At this time, given that most eligible Alabamians are vaccinated against measles, the risk for an outbreak remains low,' ADPH officials said in a statement. 'However, some individuals will need to be vaccinated as part of this ongoing investigation.' Measles is a highly contagious virus that spreads through coughing, sneezing, and close contact. In rare but serious cases, it can lead to pneumonia, brain swelling, and even death — particularly in young children, the immunocompromised, and unvaccinated populations. 'Measles vaccine is safe and highly effective in producing lifelong immunity against this potentially deadly disease,' said Dr. Karen Landers, ADPH's Chief Medical Officer and a pediatrician. 'Our citizens can protect themselves and others by ensuring that all eligible persons are vaccinated.' ADPH says anyone who may have been exposed is being contacted directly by health officials or their healthcare providers. Due to patient privacy laws and HIPAA regulations, no additional personal information about the suspected case is being released at this time. For more information on measles symptoms, vaccine eligibility, and how to protect yourself, visit: Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
GreenPower Closes Third Tranche of Term Loan Offering
VANCOUVER, BC, June 8, 2025 /CNW/ -- GreenPower Motor Company Inc. (Nasdaq: GP) (TSXV: GPV) ("GreenPower" and the "Company"), a leading manufacturer and distributor of all-electric, purpose-built, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, announces the closing of the third tranche of its previously announced secured term loan offering for an aggregate principal amount of U.S. $300,000 (collectively the "Loans"). Please refer to the Company's news release dated May 13, 2025 for more details regarding the term loan offering. In connection with the Loans, the Company entered into respective loan agreements with companies controlled by the CEO and a Director of the Company (the "Lenders"). Management anticipates that the Company will allocate the net proceeds from the Loans towards production costs, supplier payments, payroll and working capital. The Loans are secured with a general security agreement on the assets of the Company subordinated to all senior debt with financial and other institutions and will bear interest of 12% per annum commencing on the date of closing (the "Closing Date") to and including the date all of the Company's indebtedness pursuant to the Loans is paid in full. The term of the Loans will be two years from the Closing Date. As an inducement for the Loan, the Company issued 340,909 non-transferable share purchase warrants (each, a "Loan Bonus Warrant") to one of the Lenders. Each Loan Bonus Warrant entitles the holder to purchase one common share of the Company (each, a "Share") at an exercise price of U.S. $0.44 per Share for a period of twenty-four (24) months from the closing date of the Loan. In addition, one Lender will be issued an aggregate of 68,181 Shares (each a "Loan Bonus Share"). The Lenders are each considered to be a "related party" within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101") and each of the Loans and issuance of Loan Bonus Warrants and Loan Bonus Shares, as applicable, is considered to be a "related party transaction" within the meaning of MI 61-101 but each is exempt from the formal valuation requirement and minority approval requirements of MI 61-101 by virtue of the exemptions contained in section 5.5(a) and 5.7(a) as the fair market value, in each case, of the Loans, the Loan Bonus Warrants, and the Loan Bonus Shares, as applicable, is not more than 25% of the Company's market capitalization. All securities issued in connection with the Loans will be subject to a statutory hold period of four months plus a day from the closing of the Initial Loan in accordance with applicable securities legislation. For further information contact: Fraser Atkinson, CEO (604) 220-8048 Brendan Riley, President(510) 910-3377 Michael Sieffert, CFO(604) 563-4144 About GreenPower Motor Company designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to Forward-Looking Statements This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "upon", "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Loan. Although the Company believes that and the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Loan may not be used as stated in this news release, and those additional risks set out in the Company's public documents filed on SEDAR+ at and with the United States Securities and Exchange Commission filed on EDGAR at Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. ©2025 GreenPower Motor Company Inc. All rights reserved. View original content to download multimedia: SOURCE GreenPower Motor Company View original content to download multimedia:
Yahoo
7 hours ago
- Yahoo
How will the measles outbreak in Alberta affect kids?
With the measles count inching closer to the 1,000 mark in Alberta, this could mean dire consequences for the province's youngest and most vulnerable. As of Friday, the province has recorded 778 cases of the measles in Alberta, with 364 diagnosed within kids and teenagers aged five to 17 years. Over 200 cases have been diagnosed in children younger than five years old, a demographic Dr. Daniel Gregson, an infectious disease specialist says is especially vulnerable to developing serious complications from the virus. 'Measles complication rates are higher the younger you are and so, under five, you have a much higher incidence of complications which require hospitalizations,' he said. 'Common ones are pneumonia, unremitting diarrhea and then there are some rare complications like encephalitis that can result in admissions as well.' As of the time this article was published, five people are hospitalized, two of whom are in the ICU. For weeks, doctors, experts and government officials have encouraged Albertans to get vaccinated against the measles, attributing the rise in cases to poor vaccination rates over the last two decades. The reason the infection is spreading fastest among kids and teenagers is because of the low immunization rates in that demographic, according to Gregson. 'And transmission also happens when people who are not immunized gather together in large numbers and that's generally in schools.' With school almost out for the summer, that may mitigate the exponential rise in cases but with the count inching closer to 1,000, that increases the possibility of fatalities. But it's a difficult infection to control, Gregson cautioned, because it can be transmitted airborne and can stay in the air for approximately two hours after being released. 'So you can imagine, someone going to a store to pick up something,' he said. 'There could have been somebody in there who had been incubating in that four-day window and breathing in the store and then the store becomes a source of infection for other people, even when that person is no longer there.' Most adults who get the measles would see experience cold-like symptoms and a rash. But the complications arise for children who could also experience ear infections, pneumonia, dehydration and in rare cases encephalitis and blindness. On average, one patient in every 1,000 affected could die from the disease, although it's difficult to predict how that may pattern. 'We may see no deaths for the first thousand and then see three deaths in the second thousand,' he hypothesized. Should cases rise into the quadruples, kids younger than five years are most vulnerable to fatalities, he said. Ontario recorded its first death of the year from the measles outbreak in the province, after an infant born prematurely died from contracting the virus before birth. It is possible for pregnant mothers to pick up the infection and transmit to their babies pre-birth, Gregson said. 'It could be quite devastating.' A pregnant mother infected with the disease could see increased risk of a premature birth, a miscarriage, a stillborn birth or a low baby weight. The infection if passed on, could mean congenital measles for the fetus and respiratory complications post-birth.
